Pharmaceutical composition for homeostasis stabilization and pathological processes arresting in organism, and injection dosage form of this composition

FIELD: pharmacology.

SUBSTANCE: pharmaceutical composition in the form of powder, the particles of which have a size of 1 nm to 150 nm, contains calcium, carbon, oxygen, potassium, sodium, magnesium, phosphorus, sulfur and chlorine in the amounts indicated in the claims. An injection dosage form of this composition is also described.

EFFECT: pharmaceutical composition according to the invention provides replenishment of the microelements imbalance in the body and allows to accelerate the achievement of the therapeutic effect of arresting of pathological processes of various nature, including cancerous tumors.

6 cl, 4 tbl, 5 ex

 



 

Same patents:

FIELD: measurement equipment.

SUBSTANCE: method for determining a range of sizes of suspended nanoparticles consists in passage of gas (mixture of gases) containing analysed particles, through diffusion batteries of a meshed type and their introduction to supersaturated vapours of a low-volatile enlarging substance. Then, lighting of a flux of particles with a light beam and recording of parameters of light signals shaped by enlarged particles at their flying through the pointed-out area of the flux is performed. In order to improve accuracy of determination of the range of sizes, the main flux is separated into six parallel fluxes. With that, five of them are passed through five diffusion batteries with a different slip, and one of them is passed directly. Then, these fluxes pass through six devices of condensation growth and then to a field of vision of a charge-coupled device matrix and the obtained six areas of images of enlarged fluxes of particles are transmitted to a computer for an analysis of their range of sizes. Unlike known ones, the method allows performing simultaneous processing by means of a computer of six images of enlarged particles, which characterise different dimensional ranges of nanoparticles.

EFFECT: reducing the time required for measurements and improving their accuracy.

1 dwg

FIELD: physics.

SUBSTANCE: semiconductor structure for photo converting and light emitting devices consists of semiconductor substrate (1) with face surface misaligned from plane (100) through (0.5-10) degrees and at least one p-n junction (2) including at least one active semiconductor ply (3) arranged between two barrier plies (4) with inhibited zone width Eg0. Active semiconductor ply (3) consists of 1st and 2nd type spatial areas (5, 6) abutting of barrier plies (3) and alternating in the plane of active semiconductor ply (3). 1st type spatial areas (5) feature inhibited zone width Eg1 < Eg0, while 2nd type areas have inhibited zone width Eg2 < Eg1.

EFFECT: higher efficiency owing to increased photo flux and higher level of photo generation and charge carrier separation, higher probability of photon generation and lower probability of radiation-free recombination.

11 cl, 11 dwg, 5 ex

FIELD: chemistry.

SUBSTANCE: first step includes obtaining low-hydroxylated insoluble fullerenols by reacting concentrated fullerene solution in o-xylene with aqueous ammonia solution in the presence of a tetrabutylammonium hydroxide phase-transfer catalyst at 35-40°C. At the second step, the obtained low-hydroxylated insoluble fullerenols are hydroxylated to transform them into a water-soluble form by mixing with 6-15% aqueous hydrogen peroxide solution and heating for 4-5 hours at 65°C. Water-soluble fullerenols are then precipitated from an alcohol-containing solution.

EFFECT: simplifying the method while preserving quality characteristics and full extraction of the end product.

2 cl, 1 dwg, 4 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites.

EFFECT: invention provides the targeted agent delivery to liver cells, as well as higher agent accessibility and lower toxic action of selenium.

7 cl, 11 ex, 4 tbl

FIELD: physics.

SUBSTANCE: method includes forming a near-field mask on the surface of a dielectric substrate and irradiating the obtained structure with a femtosecond laser pulse. The laser radiation is first passed through a nonlinear optical crystal with a coefficient of transformation into a second harmonic equal to 5-7%. The dielectric substrate coated with the near-field mask is irradiated with the obtained bichromatic femtosecond pulse with energy density in the range of 25-40 mJ/cm2, which is less than the laser radiation energy density normally used in similar nanopatterning.

EFFECT: high resolution and low laser radiation energy consumption.

6 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to a method for hydroconversion of heavy oil fractions - feed stock, the method including a zero step and subsequent N steps. The zero step includes feeding, into a reactor, material, a catalyst precursor - aqueous solution of a Mo (VI) salt or salts of Mo and Ni, and hydrogen at pressure of 4-9 MPa under normal conditions; reacting the material and hydrogen at 420-450°C in the presence of a precursor of a suspended nanosize molybdenum or molybdenum-nickel catalyst formed in the reactor; atmospheric or atmospheric-vacuum distillation of the hydrogenation product; removing the low-boiling fraction with a boiling point not higher than 500°C as a product and returning the high-boiling fraction or part thereof into the reactor. The next steps include feeding, into the reactor, material, a catalyst precursor, the returned part of the high-boiling fraction and hydrogen; reaction thereof; said atmospheric distillation of the hydrogenation product; removing the low-boiling fraction as a product; returning part of the high-boiling fraction into the reactor; burning at 1000-1300°C or gasification of the remaining part of the high-boiling fraction, after which trapped ash-slag residues are subjected to further oxidising burning at 800-900°C and the obtained ash product, which is carbon-free, is used to regenerate the catalyst precursor and produce an industrial concentrate of vanadium and nickel. The number of steps N is determined using formulae: bd(nn+nm+1)=a+i=1nmbi+benm, N=nn+nm+1, where nn is the number of steps with recirculation, after which equilibrium output of the low-boiling fractions is achieved; nm is the number of steps with recirculation after achieving equilibrium output of the low-boiling fractions, which enables to achieve a given output of low-boiling fractions from the feed stock; bd is the given output of low-boiling fractions, wt %; a is the output of low-boiling fractions at the zero step, wt %; bi is the output of low-boiling fractions at the i-th step before achieving equilibrium, wt %; be is the output of low-boiling fractions after achieving equilibrium, wt %, be>bd.

EFFECT: high output of low-boiling fractions, low molybdenum consumption, high degree of extraction of molybdenum, vanadium and nickel from the solution, enabling calculation of the required reactor volume, obtaining an industrial concentrate of vanadium and nickel, low hydrogen consumption.

3 cl, 1 dwg, 2 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention can be used in obtaining coatings, reducing coefficient of secondary electronic emission, growing diamond films and glasses, elements, absorbing solar radiation. Colloidal solution of nano-sized carbon is obtained by supply of organic liquid - ethanol, into chamber with electrodes, injection of inert gas into inter-electrode space, formation of high-temperature plasma channel in gas bubbles, containing vapours of organic liquid. High-temperature plasma channel has the following parameters: temperature of heavy particles 4000-5000K, temperature of electrons 1.0-1.5 eV, concentration of charged particles (2-3)·1017 cm3, diameter of plasma channel hundreds of microns. After that, fast cooling within several microseconds is performed.

EFFECT: simplicity, possibility to obtain nanoparticles of different types.

3 cl, 1 dwg

FIELD: chemistry.

SUBSTANCE: invention relates to field of nanotechnologies and can be used for obtaining composite materials with high electric and heat conductivity, additives to concretes and ceramics, sorbents, catalysts. Carbon-containing material is evaporated in volume thermal plasma and condensed on target surface 9 and internal surface of collector 7. Plasma generator 3, which includes coaxially located electrodes: rod cathode 4 and nozzle-shaped output anode 5, are used. Gaseous carbon-containing material 6 is supplied with plasma-forming gas through vortex chamber with channels 2 and selected from the group, consisting of methane, propane, and butane. Bottom of collector is made with hole 8 for gas flow to pass.

EFFECT: invention makes it possible to reduce energy consumption of the process, extend types of applied hydrocarbon raw material, simplify device construction and provide continuity of the process and its high productivity.

2 dwg, 3 ex

FIELD: chemistry.

SUBSTANCE: method of obtaining a composite material includes the influence on a mixture of a carbon-containing material, filler and sulphur-containing compound by a pressure of 0.1-20 GPa and a temperature of 600-2000°C. As the sulphur-containing compound applied is carbon bisulphide, a compound from the mercaptan group or a product of its interaction with elementary sulphur. As the carbon-containing material applied is molecular fullerene C60 or fullerene-containing soot. As the filler applied are carbon fibres, or diamond, or nitrides, or carbides, or borides, or oxides in the quantity from 1 to 99 wt % of the weight of the carbon-containing material.

EFFECT: obtained composite material can be applied for manufacturing products with the characteristic size of 1-100 cm and is characterised by high strength, low density, solidity not less than 10 GPa and high heat resistance in the air.

11 cl, 3 dwg, 11 ex

FIELD: chemistry.

SUBSTANCE: invention relates to inorganic chemistry, namely to obtaining silicon-carbide materials and products, and can be applied as thermal-protective, chemically and erosion resistant materials, used in creation of aviation and rocket technology, carriers with developed surface of heterogeneous catalysis catalysts, materials of chemical sensorics, filters for filtering flows of incandescent gases and melts, as well as in nuclear power industry technologies. To obtain nanostructures SiC ceramics solution of phenolformaldehyde resin with weight content of carbon from 5 to 40% with tetraethoxysilane with concentration from 1·10-3 to 2 mol/l and acidic catalyst of tetraethoxysilane hydrolysis id prepared in organic solvent; hydrolysis of tetraethoxysilane is carried out at temperature 0÷95°C with hydrolysing solutions, containing water and/or organic solvent, with formation of gel. Obtained gel is dried at temperature 0÷250°C and pressure 1·10-4÷1 atm until mass change stops, after which carbonisation is realised at temperature from 400 to 1000°C for 0.5÷12 hours in inert atmosphere or under reduced pressure with formation of highly-disperse initial mixture SiO2-C, from which ceramics is moulded by spark plasma sintering at temperature from 1300 to 2200°C and pressure 3.5÷6 kN for from 3 to 120 min under conditions of dynamic vacuum or in inert medium. Excessive carbon is burned in air at temperature 350÷800°C.

EFFECT: obtaining nanostructured silicon-carbide porous ceramics without accessory phases.

4 cl, 4 dwg, 3 ex

FIELD: veterinary medicine.

SUBSTANCE: treatment is carried out with an aqueous solution of the preparation "Biopag-D" at a concentration of 4-2% by drifting animals through the baths with the solution having the immersion depth up to the carpal joint.

EFFECT: invention enables to treat efficiently and stress-free and prevent treatment of diseases of hooves and dew claws of animals.

3 cl, 5 dwg, 4 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: stimulating the excised liver regeneration is ensured by a 70% hepatectomy into a laboratory animal on the second day of the experiment. A liver regeneration stimulator is presented by L-norvaline administered intragastrically in a daily dose of 10.0 mg/kg every 46 hours for the first 7 days of the experiment.

EFFECT: method provides the effective stimulation of the excised liver regeneration evidenced by reducing the animals' lethality, improved hepatic microcirculation, reduced manifestation of cytolysis and enhanced synthetic function of the liver.

2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.

EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.

2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula I, where A represents O; R1 is selected from phenyl or pyrimidine, which are optionally substituted with R11; R2 represents phenyl, which is optionally substituted wby 1-3 ring carbon atoms with similar or different substituents R22, R11 represents halogen; R22 is selected from hydroxy group, (C1-C4)-alkyl, which is optionallysubstituted with 1-3 atoms of fluorine, (C1-C4)-alkyloxy, (C1-C4)-alkyl-S(O)m-; m equals 2. Invention also relates to pharmaceutical composition, which contains formula I compounds, and to method of obtaining formula I compounds.

EFFECT: formula I compounds, intended for activation of EDG-1 receptor and applied for wound healing.

15 cl, 2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to oxazolopyramidine compounds of formula (I), where A represents O; X represents (C1-C6)-alkanediyl or (C1-C6)-alkanediyloxy, where oxygen atom of (C1-C6)-alkanediyloxy is bound to group R2; Y represents pyrrolidinyl; R1 represents (C1-C4)-alkyl; R2 represents phenylene, optionally substituted by one or two carbon atoms in ring with similar or different substituent R22; R3 is selected from group, which consists of cycloalkyl-CuH2u-, where u equals 1; radical of saturated 3-10-member monocyclic ring, phenyl or pyridyl, where ring radical is optionally substituted by one or two carbon atoms of ring with substituent R31; R4 represents hydrogen; R22 represents (C1-C4)-alkyl; R31 is selected from group, which consists of halogen and (C1-C4)-alkyl. Invention also relates to (S)-l-[2-(2,6-dimethyl-4-{5-[methyl-(3,3,3-trifluoropropyl)amino]-7-propoxyoxazolo[5,4-d]pyrimidine-2-yl}phenoxy)acetyl]pyrrolidine-2-carboxylic acid, pharmaceutical composition and to method of obtaining compounds of formula (I) .

EFFECT: compounds of formula (I), intended for activation of EDG-1 receptor and applied for wound healing.

16 cl, 2 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to veterinary and can be applied in animal-breeding for stimulation of metabolic processes, and growth activity of calves. Medication for stimulation of metabolic processes and growth activity of calves includes succinic acid as energetic stimulator, with application of citric acid as activator of succinic acid, beetroot molasses as carbon component, and methionine and sodium chloride as stimulators of digestion system.

EFFECT: application of invention makes it possible to ensure expressed acceleration of growth energy in early postnatal period.

3 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: cytoflavin is administered into laboratory animals (rats) daily immediately before overheating in an air laboratory thermostat at +40±1-2°C for 45 minutes. The preparation is administered intraperitoneally in a dose of 100 mg/kg of body weight for 14 days.

EFFECT: higher body adaptability by increasing antioxidant activity and reducing a rate of lipid peroxidation products accumulation with underlying thermal exposure.

4 tbl

FIELD: medicine.

SUBSTANCE: minor amputation of the foot with the further necrectomy is performed. After the application of an antimicrobial bandage and drainage, the wound is hermetised from the environment by the creation of a negative pressure above the wound in a combination with drug treatment. The reatment is performed in two steps. At the first step the wound with the antimicrobial bandage and drainage is first hermetised from above with an adhesive film, with the creation and support of the negative pressure not lower than 80 mm Hg. Urokinase 500000 U is additionally introduced daily intravenously by drop infusion per 100 ml of physiological solution, Vessel-Due-F in a dose of 600 LU per 100 ml of physiological solution and VAP 20 - alprostadil in a dose of 40 mcg per 100 ml of physiological solution. In addition Antistax in capsules is introduced to the patient. At the second stage active 24-hour vacuum aspiration with the change of the negative pressure from 10 to 80 mm Hg within a day is carried out. Additionally introduced is Vessel-Due-F in a dose of 1 capsule with 250 LU 2 times per day between meals and Antistax. At the first and second stages Antistax is introduced in a dose of 2 capsules in the morning 30-40 minutes before meal, daily. Duration of each stage constitutes not less than 7 days.

EFFECT: increase of the treatment efficiency due to the complete and timely purification of the wound from pathological exudates, elimination of the progression of the purulent-necrotic process, increase of the regenerative activity of tissues, activation of local immunity, recovery of microcirculation and oxygenation of the affected tissues.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: method involves professional oral hygiene is carried out consisting in ultrasonic removal of supra- and subgingival dental deposits and polishing of supragingival teeth. Bite splinting and recovery of dentition integrity may be required. After dissecting a mucoperiosteal flap according to the known technique, an incision area is sanitated by means of a photodynamic therapy (PDT). The PDT is conducted with the use of a diode laser at wave length 660±5 nm and emitting power 0.5-1.0 Wt. The photosensitiser "Photoditasin" in the form of 0.5% gel is introduced by means of a cannula into dental gaps, under the dissected segments of the flap and onto the mucosal tissue for 5 minutes. The photosensitiser is washed out, and the gingival pockets are repeatedly exposed to laser light for 2-3 min in the same environment. Sterile osteoplastic material is introduced into bone defects, and the flap is sutured together.

EFFECT: effective cleansing of the surgical area, eliminating the periodontal inflammation, stimulating tissue osteogenesis and regeneration, stabilising the processes of bone tissue absorption of alveolar interdental septa and preserving the tissues.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: to correct pathologic changes in the condition of viable offspring under a cytostatic impact the medication glutoxim is introduced to female rats in a dose of 50 mcg/kg 5 days before and 5 days after the introduction of the cytostatic medication vepesid. The latter is introduced once intravenously in a maximal tolerable dose, equal to 30 mg/kg. It has been established that glutoxim can be applied as means for the correction of pathologic changes in the viable offspring of rats, obtained from coupling 3 months after the cytostatic impact.

EFFECT: application of glutoxim as the means of corrective therapy makes it possible to increase efficiency and reduce its side effects.

6 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents a pharmaceutical composition for control of pain accompanying individual's joint diseases containing hyaluronic acid, which is cross-linked by cycling a double bond in a group of cinnamic acid in partially amidated hyaluronic acid presented by formula (1) to form a cyclobutane cycle, wherein in the above formula, Ar represents a phenyl group, n is equal to an integer 2 or 3; HA represents a carboxy residue of hyaluronic acid, and m represents a relation of amidation of hyaluronic acid to all the carboxyl groups and is equal to 3-50% in relation to all the carboxyl groups, and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition represents a product for injection, wherein the pharmaceutical composition represents the product for injection, wherein the amount of the cross-linked hyaluronic acid makes 1 wt % at the total amount of the product for injection, wherein a single dose of the product for injection makes 2-3 ml, wherein the pharmaceutical composition represents a single-use preparation, which is administered every 13 weeks and more.

EFFECT: invention provides the extremely long analgesic action after the single administration, earlier onset of the analgesic action.

15 cl, 1 dwg, 5 tbl, 1 ex

Up!